Alto Neuroscience Files 8-K
Ticker: ANRO · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1999480
| Field | Detail |
|---|---|
| Company | Alto Neuroscience, Inc. (ANRO) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Alto Neuro filed an 8-K, standard stuff, no major news yet.
AI Summary
Alto Neuroscience, Inc. filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details about the 'Other Events' beyond its classification.
Why It Matters
This 8-K filing indicates a standard corporate disclosure event for Alto Neuroscience, Inc., but lacks specific operational or financial details that would immediately impact investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with no specific negative or positive events detailed, indicating low immediate risk.
Key Players & Entities
- Alto Neuroscience, Inc. (company) — Registrant
- February 12, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by Alto Neuroscience, Inc. in this 8-K filing?
The filing categorizes the event as 'Other Events' but does not provide specific details about the nature of these events within the provided text.
When was this 8-K filing submitted to the SEC?
The filing was submitted on February 12, 2025.
What is Alto Neuroscience, Inc.'s principal executive office address?
The address is 650 Castro Street, Suite 450, Mountain View, CA 94041.
What is the Commission File Number for Alto Neuroscience, Inc.?
The Commission File Number is 001-41944.
What is the IRS Employer Identification Number for Alto Neuroscience, Inc.?
The IRS Employer Identification Number is 83-4210124.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 9.9 · Accepted 2025-02-12 08:16:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ANRO New York S
Filing Documents
- d876505d8k.htm (8-K) — 24KB
- d876505dex991.htm (EX-99.1) — 12KB
- g876505g0212083145177.jpg (GRAPHIC) — 4KB
- 0001193125-25-024814.txt ( ) — 170KB
- anro-20250212.xsd (EX-101.SCH) — 3KB
- anro-20250212_lab.xml (EX-101.LAB) — 18KB
- anro-20250212_pre.xml (EX-101.PRE) — 11KB
- d876505d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Alto Neuroscience, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALTO NEUROSCIENCE, INC. Dated: February 12, 2025 By: /s/ Amit Etkin Amit Etkin, M.D., Ph.D. President and Chief Executive Officer